CELC vs STAG Comparison

Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Stag Industrial Inc is a REIT focused on the acquisition, ownership, development, and operation of industrial properties throughout the United States. Its platform is designed to (i) identify properties for acquisition that offer attractive returns across CBRE-EA Tier 1 industrial real estate markets, industries, and tenants, (ii) provide growth through the ownership of high-quality assets, property management and pursuit of acquisitions in an attractive opportunity set, and (iii) capitalize its business appropriately given the characteristics of its assets. The majority of its portfolio is single-tenant industrial properties throughout the United States. The company derives the majority of its rental revenue from its facilities located in Midwestern and Eastern U.S. cities.